Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Generation of crizotinib-resistant H3122 cells

CW Christabel Wilson
MN Mhairi Nimick
HN Hayley Nehoff
JA John C. Ashton
request Request a Protocol
ask Ask a question
Favorite

Innate resistance to crizotinib was studied by treating H3122 cells with a 10 μM of crizotinib for 24 hours and then replacing the media without crizotinib. Remaining cells were studied over 12 days following crizotinib treatment. We refer to the cells treated in this way as 24-H3122. To generate a cell line with acquired crizotinib resistant, parental H3122 cells were cultured with increasing concentrations of crizotinib starting with 0.40 μM for 24 hours, increased to 0.56 μM on day 2, and 0.80 μM on day 3. Media was changed every 3 days supplemented with fresh drug. A stable crizotinib resistant cell line was developed after 4 months of culturing in the presence of the drug and termed CR-H3122.

Copyright and License information: The Author(s) ©2017
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A